Try Calculator
← Back to Compound Library GLP-1 AGONISTS

Retatrutide

Retatrutide is the most powerful weight loss compound currently in clinical development. It works by simultaneously activating three different hormone receptor systems: GLP-1 (glucagon- like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple mechanism of action is why it produces significantly better weight loss results than semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound) in head-to-head clinical trial comparisons. To put the efficacy in perspective: semaglutide activates one receptor and produces approximately 15% average weight loss; tirzepatide activates two receptors and produces approximately 21% average weight loss; retatrutide activates three receptors and in Phase 2 clinical trials, participants lost an average of 24.2% of their body weight at the highest dose over 48 weeks. The compound was developed by Eli Lilly and is currently in Phase 3 clinical trials. It is not yet FDA approved, but it is available through research peptide suppliers. Like other incretin-based therapies, it is administered as a once-weekly subcutaneous injection. Retatrutide represents the leading edge of obesity pharmacotherapy. If Phase 3 trials confirm the Phase 2 results, it could become the most effective obesity medication ever approved for clinical use.

How It Works

To understand why retatrutide is so effective, you need to understand what each of the three receptor systems does and how their combined activation creates synergistic metabolic effects.

GLP-1 Receptor Activation

This is the same receptor targeted by semaglutide and liraglutide. When activated, GLP-1 receptors produce multiple effects:

The result is that you feel full faster, stay full longer, and your body handles glucose more effectively.

GIP Receptor Activation

This receptor enhances insulin release and appears to improve how your body processes dietary fat. Key effects include:

Retatrutide is approximately 9 times more potent at the GIP receptor than your body’s natural GIP hormone. Tirzepatide also activates this receptor, which is part of why it outperforms semaglutide.

Glucagon Receptor Activation

This is what fundamentally sets retatrutide apart from all other obesity drugs. Glucagon tells your body to release stored energy and increase metabolic rate. Effects include:

This is critical: you are not just eating less food, you are actually burning more calories throughout the day. This dual mechanism (reduced intake + increased expenditure) is why the weight loss numbers are so much higher than with drugs that only suppress appetite.

Synergistic Triple Action

The three receptor systems work together synergistically:

This comprehensive approach to weight loss through multiple complementary mechanisms is unprecedented in obesity pharmacotherapy.

Benefits

Highest Weight Loss of Any Drug in Clinical Trials

At the 12 mg weekly dose, participants in the Phase 2 trial lost an average of 24.2% of their body weight over 48 weeks. To put this in real numbers: if you weigh 250 pounds, that represents approximately 60 pounds of weight loss in under one year. Weight was still declining at week 48 when the trial ended, suggesting that longer treatment duration would produce even greater weight loss. This exceeds the results of any other obesity medication in clinical development.

Nearly Universal Response Rate

At the 8 mg and 12 mg doses, 100% of trial participants achieved at least 5% weight loss. Response rates at higher thresholds:

These response rates are higher than any other obesity medication on the market or in clinical development.

Significant Metabolic Health Improvements

In trials with participants who had type 2 diabetes, retatrutide produced:

sugar control)

These metabolic improvements occurred concurrently with weight loss, suggesting comprehensive cardiometabolic benefits beyond weight reduction alone.

Increased Calorie Expenditure

Because of the glucagon receptor activation, retatrutide does not rely solely on appetite suppression and reduced caloric intake. The compound actually increases your resting metabolic rate—your body burns more calories throughout the day even when you are not exercising. This may provide significant advantages for long-term weight maintenance after achieving weight loss goals. Increased energy expenditure can help prevent the metabolic adaptation that typically makes weight regain so common after diet-induced weight loss.

Convenient Once-Weekly Dosing

With a half-life of approximately 6 days, retatrutide requires only one subcutaneous injection per week. This is more convenient than daily medications and supports better adherence to treatment.

What the Science Shows

Retatrutide has robust clinical trial data from Phase 1, Phase 2, and ongoing Phase 3 studies conducted by Eli Lilly.

Jastreboff et al. (2023) – Phase 2 Obesity Trial

Published in New England Journal of Medicine. This landmark study established retatrutide as the most effective obesity medication in clinical development. The trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Key findings by dose:

At the 12 mg dose, approximately 63% of participants lost at least 20% of their body weight, and roughly 25% lost 30% or more. Weight loss was still progressing at week 48 when the trial concluded, indicating that longer treatment duration would likely produce additional weight reduction. Importantly, the study found that starting at a lower dose (2 mg) and titrating more slowly resulted in significantly fewer gastrointestinal side effects while achieving similar weight loss outcomes at 48 weeks compared to starting at 4 mg. This informed the recommended dosing protocol.

Rosenstock et al. (2023) – Phase 2 Type 2 Diabetes Trial

Published in The Lancet. This trial examined retatrutide in participants with type 2 diabetes, evaluating both glycemic control and weight loss. Key findings:

This demonstrated that retatrutide is effective not only for weight loss but also as a treatment for type 2 diabetes, with meaningful improvements in both outcomes.

Ongoing Phase 3 Clinical Trials

Eli Lilly has initiated multiple Phase 3 trials examining retatrutide for:

These trials will provide the comprehensive safety and efficacy data needed for regulatory approval. Sources:

Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.

with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel- group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544.

manifested by retatrutide. Cell Discovery. 2024;10:11.

Dosing Protocol

Retatrutide requires a gradual dose titration to minimize gastrointestinal side effects. The protocol below is based on the Phase 2 trial design that demonstrated the best balance of efficacy and tolerability. Standard Titration Protocol (Subcutaneous Injection, Once Weekly)

Important Dosing Considerations: Starting dose matters: Clinical trial data showed that starting at 2 mg instead of 4 mg significantly reduces the incidence and severity of nausea and gastrointestinal distress. The slower titration allows your body to adapt to the drug’s effects. Dose optimization: Many people achieve excellent weight loss results at 8 mg without needing to increase to 12 mg. If you are losing weight steadily and tolerating the dose well, there is no requirement to increase to the maximum dose. Optimize based on individual response and tolerance. Managing side effects: If gastrointestinal side effects are significant at any step in the titration, remain at that dose for an additional 4 weeks before increasing. There is no benefit to pushing through severe nausea or vomiting—these symptoms indicate you need more time at the current dose. Consistency: Administer your injection on the same day each week. Consistency in dosing timing helps maintain stable drug levels and may reduce side effect variability.

Draw Volumes by Vial Size

All calculations assume reconstitution volumes that provide practical measurements on a standard insulin syringe (100 unit capacity, with 1 unit = 0.01 mL). 10 mg Vial with 2 mL Bacteriostatic Water (5 mg/mL concentration) Dose Volume Units on Syringe 2 mg 0.40 mL 40 units 4 mg 0.80 mL 80 units 6 mg 1.20 mL Requires two draws 8 mg 1.60 mL Requires two draws Vial duration at 4 mg weekly: 2.5 weeks This concentration works well during the initial titration phase when using lower doses (2 mg and 4 mg).

10 mg Vial with 1 mL Bacteriostatic Water (10 mg/mL concentration) Dose Volume Units on Syringe 2 mg 0.20 mL 20 units 4 mg 0.40 mL 40 units 6 mg 0.60 mL 60 units 8 mg 0.80 mL 80 units 10 mg 1.00 mL 100 units (full syringe) Vial duration at 8 mg weekly: 1.25 weeks 20 mg Vial with 2 mL Bacteriostatic Water (10 mg/mL concentration) Dose Volume Units on Syringe 2 mg 0.20 mL 20 units 4 mg 0.40 mL 40 units 8 mg 0.80 mL 80 units 10 mg 1.00 mL 100 units 12 mg 1.20 mL Requires two draws

Vial duration at 12 mg weekly: approximately 1.7 weeks Vial duration at 8 mg weekly: 2.5 weeks For the 12 mg dose: Draw 100 units (10 mg), inject at first site, then draw another 20 units (2 mg) and inject at a different site at least 1 inch away from the first injection.

Reconstitution Instructions

depending on vial size and desired concentration)

Side Effects and Safety

The side effect profile is similar to other incretin-based therapies (GLP-1 agonists and dual agonists), but the triple receptor activation means gastrointestinal effects can be more pronounced, especially if dose escalation occurs too rapidly. Common Side Effects (dose-dependent):

These effects are dose-dependent. Starting at 2 mg and escalating slowly makes a significant difference in tolerability. Most gastrointestinal side effects improve after the first 2-4 weeks at each dose level as your body adapts. Less Common Side Effects:

declined)

When to Contact a Medical Professional:

Contraindications – Do Not Use If You Have:

Use With Caution If You Have:

Drug Interactions:

If you take insulin or sulfonylureas (glyburide, glipizide, glimepiride), those doses may need significant reduction to prevent hypoglycemia (low blood sugar). Retatrutide slows gastric emptying, which can affect how quickly oral medications are absorbed. Women using oral contraceptives should use backup contraceptive methods during dose titration, as absorption may be affected.

Success Tips

Start Slow and Titrate Carefully

The most common mistake is titrating too quickly. The 2 mg starting dose exists for a reason— your body needs time to adapt to these powerful metabolic signals. Clinical trial data clearly shows that slower titration produces better tolerability without compromising weight loss outcomes.

Manage Gastrointestinal Side Effects

Strategies that help:

Prioritize Protein to Protect Muscle Mass

With the potential for 24% weight loss, muscle preservation becomes absolutely critical. You must prioritize protein at every meal. Target 1.0 to 1.2 grams of protein per kilogram of body weight daily (approximately 0.5 to 0.6 grams per pound). The appetite suppression makes it easy to undereat protein. If you do, you will lose muscle along with fat, which compromises metabolic health, physical function, and long-term weight maintenance. Track your protein intake carefully.

Stay Hydrated

These drugs can reduce your natural thirst signals. Set reminders to drink water throughout the day. Dehydration makes nausea worse, causes constipation, and stresses your kidneys. Aim for at least 2-3 liters of water daily, more if you exercise.

Continue Resistance Training

Walk daily for cardiovascular health. Lift weights 2-3 times per week to preserve muscle mass. The glucagon component of retatrutide increases energy expenditure, so pairing this with exercise amplifies the metabolic effects. Do not rely on the drug alone—physical activity is essential for optimal body composition and long-term health.

Track Your Progress Systematically

Weight was still declining at week 48 in clinical trials, so be patient. Results are cumulative over many months.

Storage and Handling

Before Reconstitution:

After Reconstitution:

Legal Status and Future Outlook

United States: Not FDA approved. Currently in Phase 3 clinical trials conducted by Eli Lilly. Regulatory submission is expected around 2026 if Phase 3 trials confirm the Phase 2 efficacy and safety results. Research Peptide Market: Retatrutide is available from research chemical suppliers in lyophilized powder form for research purposes. Future Outlook: If Phase 3 trials confirm the Phase 2 results showing 24% average weight loss, retatrutide could become the most effective obesity medication ever approved for clinical use. Potential market availability is projected for late 2026 or 2027, pending successful completion of clinical trials and regulatory approval.

Frequently Asked Questions

How is retatrutide different from tirzepatide (Mounjaro/Zepbound)? Tirzepatide activates two receptors: GLP-1 and GIP. Retatrutide adds a third: the glucagon receptor. This glucagon receptor activation increases your resting metabolic rate and energy expenditure, which means you burn more calories throughout the day. This is why retatrutide produces higher average weight loss (24% vs. 21%) than tirzepatide in clinical trials. Is 24% weight loss realistic for most people? That was the average at the 12 mg dose in the Phase 2 trial with 338 participants. Individual results varied—some people lost more, some lost less. Approximately 63% of participants lost at

least 20% of body weight, and about 25% lost 30% or more. Weight was still declining at week 48 when the trial ended, so longer treatment would likely produce even greater results. What if I miss a weekly dose? If you remember within 1-2 days, take the missed dose as soon as possible. If it has been more than 2-3 days, skip that dose and resume your regular weekly schedule. Do not double dose to make up for a missed injection. Will the weight come back if I stop taking retatrutide? Studies with other incretin-based drugs show significant weight regain after discontinuation. Long-term or potentially indefinite use may be necessary to maintain weight loss results. Building sustainable healthy habits during treatment (proper nutrition, regular exercise, adequate sleep) can help reduce but not eliminate weight regain after stopping. Is nausea unavoidable? Most people experience some degree of nausea, but starting at 2 mg instead of 4 mg significantly reduces the severity. Nausea typically improves after the first 2-4 weeks at each dose level as your body adapts. The strategies in the Success Tips section can help manage symptoms. Can I stack retatrutide with other weight loss peptides or drugs? Retatrutide already activates three receptor pathways (GLP-1, GIP, glucagon). Stacking with semaglutide or tirzepatide would be redundant and significantly increase gastrointestinal side effects without adding meaningful benefit. There is no clinical data on combining retatrutide with other obesity medications, and doing so is not recommended. Does retatrutide raise heart rate? Yes, dose-dependent increases in heart rate were observed in clinical trials. The effect peaked around week 24 and then gradually declined over subsequent weeks. If you have pre-existing heart rhythm issues or cardiovascular disease, monitor your heart rate closely and discuss with a medical professional before starting. Do I need to stay at the maximum dose of 12 mg? No. Many people achieve excellent weight loss results at 8 mg without ever needing to increase to 12 mg. If you are losing weight steadily (1-2 pounds per week on average) and tolerating your current dose well, there is no requirement to increase further. Optimize based on your individual response and tolerance.

References

for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.

receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37478885/

GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:11.

agonist for the treatment of obesity and type 2 diabetes. European Journal of Clinical Pharmacology. 2024;80(6):809-820. https://pubmed.ncbi.nlm.nih.gov/38430311/

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch